Escalating dose of Casodex from 50mg daily to 150 mg daily

Phase 2

ASTRAZENECA PLC (AZNCF)

Phase 2

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

No Catalysts Found

No catalyst events have been recorded for this drug yet.

Competitive Landscape

9 competitors in Prostate Cancer

SOPHPrGIS

CADLaglatimagene besadenovec

Phase 3

SNYCabazitaxel XRP6258

Phase 2

4503.TCP-461

Phase 2

BTAIBXCL701 plus Pembrolizumab

Phase 2

View Full Landscape

Drug Information

Target Indication

Prostate Cancer

Clinical Trial

NCT00554086

Last updated: 8/18/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Drug Science

Mechanism of action & safety profile

Developer

AZNCF

ASTRAZENECA PLC

Biotechnology•North America•NASDAQ

Related Pipeline

propranololPhase 3

Migraine Without Aura

Quetiapine SRPhase 3

Anxiety Disorders

Ceftaroline fosamilPhase 3

Infections

Erlotinib 150/100 mgPhase 3

Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non Small Cell Lung Cancer

Ticagrelor orodispersible tabletsPhase 3

ST Elevation Myocardial Infarction

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts